Phase 1 study indicates allogeneic cytokine-induced memory-like natural killer cells plus n-803 may induce tumor regression in advanced head-and-neck cancer patients

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced findings from a phase 1 study showing that allogeneic cytokine-induced memory-like (ciml) natural killer (nk) cells used in combination with immunitybio's il-15 superagonist n-803 may induce tumor regression associated with persistent ciml nk cell expansion in advanced head-and-neck cancer patients. the results indicate the potential for a new treatment approach for th.
IBRX Ratings Summary
IBRX Quant Ranking